OVERVIEW

A Managed Care Review: Approaches to Mitigate Blindness Associated with Neovascular Age-Related Macular Degeneration is organized by Pharmacy Times Continuing Education (PTCE).

Dates:
Start Date:- Jul 13, 2019
End Date:- Jul 13, 2020.

Intended Audience:
Pharmacists and managed care professionals

Accreditation:
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs).

Course Description:
Age-related macular degeneration (AMD), which affects approximately 8 million Americans, has dramatically changed with the introduction of biologic therapies. Two approved and 1 off-label anti-vascular endothelial growth factor (VEGF) biologics are now used effectively and safely to prevent vision loss and blindness. Healthcare costs associated with drug therapy, hospitalization, and reduced productivity for AMD-related care are significant; indirect costs are high and grow as vision loss progresses. Early, aggressive treatment can help control costs later in life. This activity will help managed care professionals become more aware of the prevalence of AMD, economic implications of various treatment plans, and opportunities to optimize the care of patients through counseling and therapy monitoring.

Educational Objectives:
Upon completion of this activity, participants should be able to:
• Examine the prevalence, pathophysiology, and risk factors of neovascular age-related macular degeneration (nAMD).
• Examine routes of administration, dosing, safety, clinical efficacy, and clinical role in treatment for FDA-approved and emerging anti-VEGF treatments.
• Examine the healthcare utilization costs associated with blindness and AMD.
• Apply knowledge of economics, treatment options, and clinical data to develop cost management strategies for AMD.

Additional details will be posted as soon as information is available.